All In Biotech

Drug Trial Radar · NCT00182312

Caffeine for Apnea of Prematurity (CAP)

Efficacy and Safety of Methylxanthines in Very Low Birthweight Infants

Last checked: Nov 20, 2026Latest source record: Mar 22, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 2,000 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,000

Planned (sponsor's estimate)

Start

Oct 1999

Primary completion

Mar 2007

Study completion Jul 2016

Sponsor

Lead sponsor
McMaster UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Canadian Institutes of Health Research (CIHR); National Health and Medical Research Council, Australia
First posted
Sep 16, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Prevention
Who can join
All sexes, up to 10 days
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

At least 5 of every 1000 live-born babies are very premature and weigh only 500 to 1250 grams at birth. Approximately 30-40% of these high-risk infants either die or survive with lasting disabilities. The aim of this research is to reduce this heavy burden of illness. A multi-center randomized controlled trial has been designed in which 2000 very low birth weight infants will be enrolled. Our goal is to determine whether the avoidance of methylxanthine drugs will improve survival without disability to 18 months, corrected for prematurity. Methylxanthine drugs such as caffeine are used to prevent or treat periodic breathing and breath-holding spells in premature infants. However, there is a striking lack of evidence for the long-term efficacy and safety of this therapy. Methylxanthines block a naturally occurring substance, called adenosine, which protects the brain during episodes of oxygen deficiency. Such episodes are common in infants who are treated with methylxanthines. It is possible that methylxanthines may worsen the damage caused by lack of oxygen. Therefore, this trial will clarify whether methylxanthines cause more good than harm in very low birth weight infants.

Conditions

  • Apnea of Prematurity

Interventions

  • Caffeine citrate injectionDrug

    Loading dose: 20 mg/kg administered over at least 30 minutes via IV infusion or over at least 10 minutes via slow IV injection. Daily maintenance dose (to commence at least 24 hours after loading dose): 5 mg/kg, administered over at least 10 minutes via IV infusion, or over at least 5 minutes via slow IV injection. Maintenance dose to be adjusted for body weight every 7 days. If indicated, maintenance dose may be increased to a maximum of 10 mg/kg. May be given orally once full enteral feeds are established. Duration of treatment: discontinue after infant has tolerated at least 5 consecutive days without positive pressure support AND when the infant is judged by the attending clinician to be no longer a candidate for methylxanthine therapy.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. combined rate of mortality and neurodevelopmental disability in survivors at a corrected age of 18 months.Time frame: corrected age of 18 months

Locations

34 sites in 9 countries. Site status is shown where the registry gives one.

  • Brooklyn Hospital Center

    Brooklyn, New York

  • Canberra Hospital

    Canberra, Australian Capital Territory, Australia

  • Women's & Children's Hospital

    Adelaide, South Australia, Australia

  • Mercy Hospital for Women

    Melbourne, Victoria, Australia

  • Royal Women's Hospital

    Melbourne, Victoria, Australia

  • Centre Hospitalier Universitaire de Quebec

    Québec, Canada

  • Foothills Hospital

    Calgary, Alberta, Canada

  • Children's & Women's Health Centre of BC

    Vancouver, British Columbia, Canada

  • Victoria General Hospital

    Victoria, British Columbia, Canada

  • St. Boniface General Hospital

    Winnipeg, Manitoba, Canada

  • Moncton Hospital

    Moncton, New Brunswick, Canada

  • McMaster University

    Hamilton, Ontario, Canada

  • Kingston General Hospital

    Kingston, Ontario, Canada

  • Ottawa Hospital

    Ottawa, Ontario, Canada

  • Mount Sinai Hospital

    Toronto, Ontario, Canada

  • Sunnybrook & Women's College Health Science Centre

    Toronto, Ontario, Canada

  • Windsor Regional Hospital

    Windsor, Ontario, Canada

  • Royal Victoria Hospital

    Montreal, Quebec, Canada

  • University of Sherbrooke

    Sherbrooke, Quebec, Canada

  • Royal University Hospital

    Saskatoon, Saskatchewan, Canada

  • Ludwig Maximilian University

    Munich, Germany

  • University of Tuebingen

    Tübingen, Germany

  • Soroka University Medical Center

    Beersheba, Israel

  • Meir General Hospital

    Kfar Saba, Israel

  • Kaplan Medical Center

    Rehovot, Israel

  • Academisch Medisch Centrum

    Amsterdam, Netherlands

  • University Hospital Maastricht

    Maastricht, Netherlands

  • Astrid Lindgren's Children's Hospital

    Stockholm, Sweden

  • University Children's Hospital Basel

    Basel, Switzerland

  • University Hospitals of Geneve

    Geneva, Switzerland

  • University of Zurich

    Zurich, Switzerland

  • South Cleveland Hospital

    Middlesbrough, United Kingdom

  • Royal Victoria Infirmary

    Newcastle upon Tyne, United Kingdom

  • Royal Maternity Hospital

    Belfast, Northern Ireland, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.